GlassScriptPhysician profile
Adrian Avila
NPI 1619545936
$5,075.22
in general payments reported to CMS, 2019-2025
21 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $1,151 · 2023: $844 · 2024: $885 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460 · Education: $7.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.10 |
| Education | $7.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.18 | 2021-2025 | |
| Alkermes, INC. | $887.56 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $677.04 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $426.37 | 2022-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.70 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $281.79 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $279.53 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $273.55 | 2022-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $190.68 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $179.36 | 2022-2025 | Rexulti |
| Corium, LLC | $118.97 | 2023-2025 | Azstarys |
| Tris Pharma INC | $63.25 | 2024-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $50.07 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $42.91 | 2025 | Cobenfy |
| Indivior INC. | $38.50 | 2022-2023 | Perseris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.08 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $23.57 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $21.04 | 2025 | Trintellix |
| Novo Nordisk INC | $20.74 | 2025 | Ozempic, Rybelsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.83 | 2025 | |
| Pfizer INC. | $13.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.